Welcome to SFA Therapeutics

A New Paradigm in Drug Development

About Us

SFA Therapeutics, LLC is a development-stage bio-pharmaceutical startup company focused on a new advancement in the treatment of chronic inflammatory disease-- the use of microbiome-derived metabolites as drugs

 A completely new approach to drug discovery and development

Deriving drugs from bacterial metabolites found in man means no genotoxicity, faster clinical development and safer treatments

Our pipeline includes treatments for Psoriasis, Liver Cancer (Hepatitis B, NASH and HCC), Ophthalmic Diseases, Cytokine Release Syndrome- a side effect in CAR-T,  and other diseases. 

Safer, Faster to Market and Lower R&D Cost

Our microbiome-derived drugs are derived from natural substances, and enable a new platform for developing treatments which have the potential to treat over 85 chronic inflammatory diseases currently afflicting patients;  providing safer treatments than current therapies.    

Current Focus

Pipeline

  Our first drug is an oral treatment for psoriasis

 

• Oral drug (tablet or capsule)

• Enteric-coated

• Extended release

• Twice per day dosing (potential for once daily)

• Low side-effect profile; not an MAB, no antibodies

• Low cost of goods

• Can be combined with marketed drugs to lower side effects and increase overall efficacy


Summary of the Psoriasis Market Landscape  

• Current treatments are expensive

• Follow-up healthcare burden, testing and follow-up cost is high

• Co-morbidity is high (potential to treat with the same SFA drug)

• Efficacy is not always sustained; patients often need to switch therapies

• Patient, prescriber and payer satisfaction is low

• “Patients are afraid to try current treatments”- the market is underserved


SFA’s drug addresses major unmet needs in the psoriasis market  

 
Data:  

In a small case-controlled human trial, a Proof of Activity treatment effect was observed.


A Phase 2A Proof of Concept trial is planned for 2018-2019.  


Our second drug candidate is focused on Hepatitis B, NASH and Hepatocellular Carcinoma

 
Data:  

In-vitro data demonstrated a significant reduction in both the number of hepatocellular carcinoma tumors and in tumor sizes, in HBX mice.


Core Team

CEO:  Dr. Ira Spector  Experienced drug developer at Wyeth, Pfizer, Allergan & ICON, has been involved with 33 NDAs & 12 medical devices. Co-founder of 3 startups. PhD, University of Medicine & Dentistry, NJ, MBA, Drexel University, B.S. Physics, B.S. E.E., Washington University, St. Louis.


CSO:  Dr. Mark Feitelson  Co-inventor; Professor at Temple University, expert in hepatitis and liver cancer; prior research at Jefferson Fox Chase & Stanford University. PhD, David Geffen School of Medicine at UCLA, B.S. Biology, University of California, Irvine.


CDO:  Dr. Alla Arzumanyan  Co-inventor;  Assistant Professor at Temple University, formerly at Jefferson University; expert in hepatitis B & GI microbiome metabolites. PhD, Yerevan State University, Armenia.

 

Current Scientific and Business Advisors:


Dr. Chris Gallen, MD, PhD, CEO, WEX Pharmaceuticals

David Kunin, ex-FDA, regulatory affairs advisor

Sandra Stoneman, Duane Morris, corporate counsel

Todd Wallach, CEO, Evogen, business advisor

K&L Gates and Riverside Law, IP Counsel

• External advisors in finance, ophthalmology, dermatology, 

  clinical trial design and rheumatology  



Intellectual Property

Five provisional patents filed: 


1. Cancer Prevention in Liver Disease

2. Treatment of Psoriasis and Associated Skin Diseases

3. Combination Therapy in Psoriasis/Skin Diseases

4. Oral Drug for the Treatment of Uveitis

5. Prevention of AutoImmune Diseases in C-Section 

Neonates 

      

Five additional patents planned by the end of 2017 


Composition of Matter Patent filed. 



 

 

Contact Us

For more information

Dr. Ira C. Spector, CEO

 

SFA Therapeutics

Suite 400, 610 Old York Road, Jenkintown, Pennsylvania 19046, United States

267-584-1080